7086-29-5

Usage

Molecular Structure

1-Phenylcycloheptane-1-carboxylic acid consists of a heptane ring (seven-carbon chain forming a cyclic structure) and a carboxylic acid functional group (-COOH) attached to a phenyl group (-C6H5).

Physical Properties

It is a white solid compound that is sparingly soluble in water.

Uses

The chemical is used in the synthesis of various pharmaceuticals and drug intermediates.

Biological Activities

It has been studied for its potential biological activities, such as anti-inflammatory and antimicrobial properties.

Material Development

The compound has been investigated for its potential to serve as a building block in the development of new organic materials and polymers.

Upstream product

• 7278-77-5 (1-chloro-cycloheptyl)-phenyl-methanone 
• 502-49-8 cycloactanone 
• 936-65-2 α-hydroxymethylidenecyclooctanone 
• 108-86-1 bromobenzene 
• 60433-00-3 methyl cycloheptanecarboxylate 
• 94163-02-7 methyl 1-phenylcycloheptanecarboxylate 
• 32730-85-1 cycloheptanecarbonitrile 
• 6004-52-0 cycloheptyl(phenyl)methanone 
• 2082-21-5 1-phenylcycloheptanol 
• 502-42-1 cycloheptanone 
• 497-19-8 sodium carbonate 
• 124-38-9 carbon dioxide 
• 32621-88-8 1-methoxy-1-phenylcycloheptanol 
• 140-29-4 phenylacetonitrile 

Downstream Products

• 94163-02-7 methyl 1-phenylcycloheptanecarboxylate 
• 1194737-01-3 (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridin-2-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane chloride 
• 1194737-07-9 (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridin-2-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane bromide 
• 1196090-97-7 (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridin-4 ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane chloride 
• 1194737-31-9 (R)-1-[(5-Fluoro-pyridin-2-ylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane chloride 
• 1196091-05-0 (R)-1-Phenylcarbamoylmethyl-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane bromide 
• 1196091-06-1 (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyrimidin-4-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane chloride 
• 1196091-07-2 (R)-1-[(2-Fluoro-phenylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane bromide 
• 1196091-14-1 (R)-1-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane formate 
• 1196091-16-3 (R)-1-[2-(4-Fluoro-phenoxy)-ethyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane formate 
• 1196091-23-2 (R)-1-[(5-Fluoro-pyridin-3-ylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane chloride 
• 1196091-34-5 (S)-1-(3-Phenoxy-propyl)-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane formate 
• 1196091-40-3 (R)-1-[(3,5-Difluoro-phenylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane bromide 
• 1196091-47-0 (R)-1-[(2,6-Difluoro-phenylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane bromide 

Relevant academic research and scientific papers

Stereospecific Construction of Contiguous Quaternary All-Carbon Centers by Oxidative Ring Contraction

Oxidative ring contraction of cyclic α-formyl ketones was facilitated by the action of H2O2under operationally simple and environmentally benign reaction conditions. The process was highly regioselective and enables stereospecific construction of contiguous quaternary all-carbon centers from stereodefined all-substituted all-cyclic ketones. The asymmetric syntheses of (+)-cuparene and (+)-tochuinyl acetate were also successively achieved by taking advantage of this novel protocol.

New Strategy for Forging Contiguous Quaternary Carbon Centers via H 2 O 2 -Mediated Ring Contraction

Stereospecific construction of contiguous quaternary carbon centers constitutes a major challenge in natural product synthesis. A general protocol that enables stereospecific construction of all stereoisomers of such a moiety remains elusive. In this article, we will discuss the oxidative ring contraction of all-substituted cyclic α-formyl ketones mediated by H 2 O 2, which provides a facile access to the stereospecific construction of contiguous quaternary carbon centers.

HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD

A novel series of muscarinic receptor antagonists was developed, with the aim of identifying a compound with high M3 receptor potency and a reduced risk of dose-limiting side effects with potential for the treatment of COPD. Initial compound mo

QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS

The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for’ the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.

QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS

The invention provides named compounds of formula (I ), wherein R4 is a N- sustituted quinuclidine ( I ) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for' the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.

QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, Het1, n, Y and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation.

NOVEL COMPOUNDS 514

The invention provides compounds of formula (I), wherein R1, R2, R3, R4, R5, g, h and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing the

QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS

The invention provides compounds of formula (I) wherein R4 is a group of formula (II) or (IIIa) or (IIIb) and R1, R2, R3, R5, a, b and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation (I), (II), (IIIa), (IIIb).